

Oxidative Stress and Its Role in Insulin Resistance in Polycystic Ovary Syndrome

Farideh Zafari Zangeneh¹

1. Associate Professor of the Reproductive Health Research Center, Tehran University of Medical

2. ARTICLE INFO

Keywords:

*Oxidative stress,
Insulin resistance,
polycystic ovary
syndrome (PCOS).*

ABSTRACT

The production of reactive oxygen species (ROS) can alter macromolecules in living organisms and can result in a wide range of injuries. Recently, oxidative stress has been known as a key mechanism in insulin resistance. Today, oxidative stress (OS) status assessment is performed using circulating markers such as malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GPX). Polycystic ovary syndrome (PCOS) with a prevalence of 4-12 % is the most common endocrine-metabolic disorder in the reproductive age of women. PCOS is now recognized as an important metabolic disorder. Insulin resistance (IR) independent of obesity in PCO women has been identified as a predisposing factor for type2 diabetes and cardiovascular disease (CVD). Oxidative stress index is strongly associated with PCOS. The role of oxidative stress is very important but not considered but it plays an important role in the development of IR. In this mini review, we presented a viewpoint about the key role of brain's IR/OS in the brain-ovarian axis in the women with PCOS. These review articles helps us to better understanding of the PCO etiology



1. Introduction

1. Polycystic ovary syndrome (PCOS)

This syndrome is associated with endocrine/metabolic disorders and infertility. Its prevalence is 4-12% in women of reproductive age (1). In Iran, the prevalence of this syndrome has been reported from 7.1 to 14.6 (2). PCOS is heterogeneous in clinical signs and the anovulation in these women is the main cause of infertility. The anovulation accounts approximately 75% of infertility in these women (3). In the childhood, early puberty, in adolescence hirsutism, menstrual disorder and, after post-adolescence with infertility and glucose intolerance and finally in middle age is associated with diabetes mellitus, cardiac vascular disorders (CVD) and blood pressure (BP). PCOS etiology is still unknown. The cause of this syndrome can be the complex pathology with endocrine/metabolic dysfunction in the two brain axes: hypothalamus-pituitary-adrenal (HPA) and gonadal (HPG). The metabolic pathways in ovary like: steroids and gonadotropin regulators, glucose metabolism regulators, adipose signaling and important insulin signaling pathways that all of them are destroyed in this syndrome (4). Polycystic ovary morphology (PCOM) is one of the most valuable clinical finding in this chronic syndrome. These morphological changes were first described by Chereau in 1844 (5). Diagnostic criteria for this syndrome have been established by the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproduction and Infertility (ASRM) in 2003, based on extensive studies over the past several decades with the so-called Rotterdam criteria (6). Some researchers doubt whether this syndrome is an evolutionary paradox or a sexual conflict, which may be related to heredity, environmental factors and even intra-fetal factor or factors (7). As a syndrome, PCOS is also treated on the basis of precise clinical symptoms, and therapies mainly include ovulation induction, lowering the levels of androgen, luteinizing hormone (LH), insulin resistance, and surgery (8). The assisted reproductive technologies (ART) method is another method (in vitro oocyte maturation) for infertile patients with PCO.

2. Oxidative Stress (OS)

Oxidative stress is an important factor for the instability at intracellular homeostasis. Any factor or many conditions can lead to the production of reactive oxygen species (ROS) which is called oxidative stress. In the normal cells, there must be a relative balance between prooxidants and antioxidants for internal stability. Disruption of this balance can lead to oxidative stress by increasing prooxidants or decreasing antioxidants, so that prolonged these imbalance can easily cause serious injury for normal cells (9).

2.1. Oxidants

Oxidation is a chemical process for destroying the electrons of an atom or molecule that can be critical (10). Oxidants are chemical compounds that produce molecular oxygen (prooxidants) that must be neutralized by antioxidants. The cell can tolerate oxidative stress to a limited extent, but in severe status, damaged cell membrane may cause a pathological complications with the impaired of cell homeostasis (11).

Today, antioxidants are used as chemical prophylaxis for inhibiting of the free radicals (12).

2.2. Free radicals

Free radicals can easily enter in the chemical reaction via sharing of their single electrons. Oxygen free radicals are the most invasive agents in the biological systems that can damage the chain pathways. These agents are generally known as "reactive oxygen species" (ROS). ROS contains free and non-free radical oxygen molecules that are involved in the generation of oxidative stress (13). Oxidative stress by overproducing reactive oxygen species and accumulating them during environmental stress can even damage the crop and reduce the quality and quantity of the crop, even in plant products. The production of reactive oxygen species as a determining factor can cause lipid peroxidation, inactivation of enzymes and oxidative damage of cellular DNA. The main site of free radical production is mitochondria (14).

2.3. Mitochondria and oxidative stress

The critical role of mitochondria in cell energy homeostasis is crucial, so they are involved in biogenetic processes including: insulin signaling, cell survival control, and also the major site of ROS production in the cell during respiratory reactions for their intracellular respiratory chain. Thus, abnormalities in the mitochondria function can be highly linked to the progress of peripheral IR (15, 16). Mitochondrial-ROS (mtROS) producing plays an important role in the release of pro-apoptotic proteins such as cytochrome-c to produce of caspase initiation and apoptosis. Therefore, there is evidence for the direct relationship between mitochondria, oxidative stress, and cell death (17). In addition, mitochondria-ROS producing during cellular metabolism can be generated in response to various environmental stimuli including: growth factors, inflammatory cytokines, ionizing radiation, UV, chemical oxidants, chemotherapy, hyperoxia, toxins and metals (18). Apart from the traditional role of mitochondria in metabolic processes and ROS signaling it has been dynamically implicated in innate immunity (19). "Recently, it has become clear that some innate immune cells are epigenetically reprogrammed or "imprinted" by past experiences. These "trained" innate immune cells display altered inflammatory responses upon subsequent pathogen encounter" (20). The reactive oxygen species in mitochondria (mtROS) as the signaling molecules can drive production of the inflammatory cytokine and T cell activation. Increasing of mtROS level can lead to autoimmune diseases, CVD, cancers (21). Findings from recent decades show that dysfunction of the endothelial cell by inflammatory and oxidative stress can be associated with the pathogenesis of diabetes for development of premature atherosclerosis. Therefore, antioxidants can be effective role in suppressing of the inflammatory cytokines secretion in the human coronary artery endothelial cells (22).

2.4. Antioxidants

Antioxidants must be control the autoxidation by disconnecting the transmission of free radicals or by preventing of the formation of free radicals for reduction of oxidative stress, improve the immunity function, and ultimately, extend lifespan (23). Antioxidants are generally the chemicals for assessment of the oxidative stress status that can be divided into reactive oxygen species, ROS diluents or antioxidant chemicals and transcription factors regulating ROS production. It is difficult to evaluate oxidative stress in different diseases by similar markers or biomarkers because the markers used in a particular disease are limited and must always be carefully filtered (14). They contain a variety of antioxidants as counter-attacking agents on both sides of their membranes. In the physiological response, the body must be able to defend itself against oxidative stress through two physical and chemical processes.

Physical defense is the limiting of the free radicals activity in their production sites within the cell. Enzymes that can neutralize the dangerous forms of reactive oxygen are considered the physical defense. Enzymatic and non-enzymatic antioxidants defense shows a serious role in the preserving of normal ROS levels. Vitamin A, C and E can disrupt the primary chain reactions by giving electrons to free radicals (24). DNA care is another of the body's intracellular defenses against oxidative damage. Although the complex stress responses with proteins and cell membranes can trigger the process of cell suicide (apoptosis) (25). One of the cellular oxidative damages is DNA damage and cytotoxicity; so many studies are under way to develop new methods and strategies in the prevention and treatment of cancer. However, the variations of the mitochondrial genome and dysfunction have been increasingly recognized as a significant donor in PCOS, CVD and cancer. For example, the mitochondrial DNA mutations can be the other target of assessments on PCOS heritability (26).

2.5. How does oxidative stress profile?

Today, the relationship between oxidative stress and chronic diseases such as: cardiovascular disease (CVD) (27), type2 diabetes (28), psychological disease (29), cancer (30), PCOS (31), Alzheimer (32), Multiple sclerosis (MS) (33) and other diseases have been identified. Many different components and factors that produced in oxidative stress can be investigated. This assessment is called Oxidative Stress Index (OSI). This index is a new strategy for

represents the oxidative stress status in the disease process. OSI is beneficial for investigation and management in clinical medicine (34). So, several indexes have been suggested for measuring of OS in humans includes: Oxidative Stress Index (OSI), Oxidative Stress Score (OSS), Glutathione Ratio (GSSG/GSH), Tiol Ratios (-SH/TT, -SS/-SH, and -SS/TT), and OXY-index (35). All of oxidative stress index parameters are significantly higher in women with PCOS than controls. Also, fetuin-A levels as an indicator for IR in serume of PCO patients is higher in the PCOS group than control (36, 37).

3. Polycystic ovary syndrome (PCOS) and oxidative stress (OS)

Polycystic ovary syndrome (PCOS) as a chronic heterogeneous disease is often associated with insulin resistance (IR), hyperandrogenism, chronic inflammation and oxidative stress (OS) (4). Many studies have shown that the level of operating system of oxidative stress in PCO women is significantly higher than normal subjects. This assessment of the oxidative stress status has been performed by using of circulating markers of PCO wome such as malondialdehyde (MDA) in serum and erythrocyte (38) are higher than normal women. Superoxide dismutase (SOD) in serum, erythrocyte and follicular fluid (39) is higher than normal like Xanthine oxidase (XO) in serum of these patients (40). But glutathione peroxidase (GPX) (41) and 8-Hydroxydeoxyguanosine (8-OHdG) in serm of women with PCO are lower than normal women (42). These markers are suitable for assessment of oxidative stress in PCOS (43). The levels of operating system of the oxidative stress are significantly associated with factors such as obesity (44), insulin resistance (IR) (45), androgens (46), and chronic inflammation (47). Studies of the last two decades show that reactive oxygen species (ROS) in follicular fluid, granulosa and mononuclear cells (48, 49), total oxidant status (TOS) and finally oxidative stress index (OSI) in serum of PCO women are higher than normal women (50, 51).

Although oxidative stress has been recognized as a potential motive in polycystic ovarian pathology, it is still unclear whether abnormal oxidative stress levels in patients with PCOS are the cause of this syndrome or are directly related to its potential complications?

3.1. Relationship between polycystic ovary syndrome (PCOS) and oxidative stress (OS)

3.1.1. Sympathetic nervous system (SNS), PCOS and OS:

There are many factors between the complications of PCOS and the hyperactivity of the SNS (52). The anatomical findings in animals (53) and humans (54) confirm an increase of the chatecolamine nerve fibers in the ovaries. One of the most potent markers for the SNS activity is nerve grough factor (NGF). Dissen et al. showed that the ovarian NGF is higher than normal subjects in the modeling mice and women with PCO (55) but serum NGF was significantly lower in these women (56). Kishi et al. (2012) reported that oxidative stress in the brain is an important factor for regulating of SNS activity and therefore, this is can be the major cause of hypertension (57). PCOS is associated with 1) metabolic disorders (58), 2) the high risk of cardiovascular disease (CVD) (59) and 3) diabete in the context of overactivity of SNS (4). The hyperactivity of SNS in both PCOS and metabolic syndrome (MetS) are associated with the involvement of two ADR- α 2 (60) and ADR- β 2 (61).

The role of central noradrenaline (NA) is very important in the brain-ovary axis. Cerebral NA originates from the Locus coeruleus (LC) neucleus as the smallest neucleus in the midebrain organization. LC is the important site for the largest accumulation of NA neurons that adjacent to the fourth ventricle in the brain bridge or pontine. Our study in 2012 showed that chemical degradation of the LC neucleus in the PCO modeling rats changes the follicle's morphology. These morphologic polycystic ovary (PCOM) changes included a small size of antral follicles and hypertocosis (enlarged thecal cells) (62). Another important role of NA in the brain-ovary axis is control of LH surge. LH surge is begun by a dramatic elevation of estradiol production by the preovulatory follicle. The LH surge stimulates the luteinization process in granulosa cells and also stimulates the synthesis of progesterone responsible to the midcycle FSH surge. LH hypersecretion in PCO women is probably due to enhanced sensitivity of pituitary to gonadotropin releasing hormone (GnRH) or changes

in pattern of GnRH secretion. Therefore, changed production of sex steroid, metabolic dysfunction, and obesity could be all contribute to the changes in the pattern of LH secretion (63). Changes in LH surge pattern in brain-ovary axis and elevated level of NA metabolites in the urine of women with PCO suggest an overactivity of SNS that has been demonstrated in animal and human studies (64). By increasing the activity of ovarian SNS, catecholamine homeostasis is altered and leads to a selective down-regulation of beta-adrenoceptor at the level of interstitial cells in thecal layer and suppresses the activity of this adrenoceptor in the ovary (65).

The insulin signaling pathway as a metabolic process in PCOS is directly related to the level of SNS activity. Desai and et al in 2014, reported that lipid peroxidation (MDA) and total antioxidant capacity (TAC) as indicators of antioxidant status with fasting blood glucose, insulin, and uric acid in non-obese patients with PCO accompanied significant changes in both study and control groups (66). Bañuls et al in 2017 suggested that polycystic ovary syndrome is associated with insulin resistance, which can also lead to metabolic syndrome (MetS). Therefore, oxidative stress and leukocyte-endothelium interactions are PCOS-dependent and thus their results support this hypothesis that there is a correlation between metabolic changes, increased ROS production, endoplasmic reticulum stress, and leukocyte-endothelium interactions in PCOS that ofcourse all of these events can lead to cardiovascular complications (67).

3.1.2. Insulin resistance (IR), PCOS and OS:

Insulin resistance (IR) was first introduced in 1960 by Dr. Yalo and Bresson.

IR is a metabolic state with too much insulin production against the normal response, because insulin sensitivity reduces under such conditions. Then this resistance can reduce the insulin response to the all of metabolic effects in the body. One of the most important features of PCOS is type2 diabetes with IR, which is associated with obesity and CVD (68). Insulin in the brain performs metabolic, neurotropic, neuromodulatory and neuroendocrine functions. Energy homeostasis is one of the important metabolic and neuromodulatory functions of brain's insuline (69). Insulin is a potent neuromodulator in the energy homeostasis and studies have shown that injecting of insulin antibody into the intermedia nucleus of the rats hypothalamus causes overeating and obesity (70, 71). In this brain response, insulin supplies intracerebral energy and then stores it into neurons. This energy production pathway is accompanied by activation of ADR- β and the detachment or extrusion of glucose from glycogen stores of brain glial cells that occur within astrocytes. Then, by converting astrocytic glycogen into glucose, the glucose is stimulated by insulin via glucose carrier (GLUT1) and transferred to the extracellular fluid. This glycogen is actually an additional source of energy for the neurons which is dependent on the SNS. These results indicate 1) sensitivity rate of brain tissue to the both glucose and insulin and 2) an important role of NA on homeostasis processes (72). IR in the obese PCO women can disrupt the synthesis of androgens or through the adipocytokines can directly or indirectly, affect on the brain-ovarian axis. Therefore, it affects on the hypothalamic secretion and the peripheral metabolism of steroids (73). Studies have shown that CVD (74), diabetes (75), sleep apnea or respiratory arrest (76), polycystic ovary syndrome (77, 42), and metabolic syndrome (78) are all associated with the overactivity of SNS (79). A meta-analysis of PCOS confirms the presence of PCOS-related insulin resistance (IR) and metabolic syndrome in non-obese patients (80) and obese women (81).

3.1.3. Hyperandrogenism, PCOS and OS

Hyperandrogenism is a prominent feature of PCOS. Testosterone level in women with PCO is usually higher than normal women. Codner's hypothesis in 2009, was based on the prevalence of type1 diabetes in patients with PCO which; both ovaries and adrenals are exposed to high androgen and insulin levels and the PCO is a frequent complaint of the women with Type1 diabetes (82). The abnormal gonads' steroidogenic activity that observes in patients with PCO is due to the high level of androgen in the ovaries that inhibits follicular maturation and helps to the negative process in ovulation. Hyperandrogenemia

itself can cause the desensitization of hypothalamic response to progesterone/estrogen negative feedback system which; further increases the secretion of GnRH and ovarian androgen production (83).

Studies in the culture medium show that, steroidogenesis activity of single cells in PCO women is higher than in the control group. Increased levels of androgen secretion increased the activity of the enzymes after repeatedly culturing the cells. Thus, this hyperandrogenism produced the combination of testosterone, such as β 3-hydroxy dehydrogenase, CYP17 and CYP11A (73). Hyperandrogenism and oxidative stress are associated in PCOS (49), but we do not know whether the hyperandrogenism can activate oxidative stress in PCO women or not.

4. Metabolic syndrome and oxidative stress

Reproductive and metabolic disorders are associated with PCOS. These disorders are more common in obese people. Reports suggest that metabolic syndrome, similar to PCOS, is associated with insulin resistance (IR). IR may be a suitable central and peripheral stimulus for the other disorders in the two syndromes (74, 80). IR can via overproducing of insulin, can reduce the capacity of beta cells and predispose the patient to type2 diabetes. IR may also damages insulin-sensitive organs, including liver and kidney. The hyperinsulinemia reflex can transmit triglycerides from the liver into the bloodstream, thereby lowering HDL and increasing LDL cholesterol levels. Dyslipidemia (HDL/LDL imbalance) as one of the factors of metabolic syndrome can easily increase the risk of CVD by free radical invasion especially in the case of triglycerides, because it has not been neutralized via antioxidants. As a result, this imbalance between oxidants and antioxidants can lead to lipid peroxidation under oxidative stress, and may be an effective factor in the development of atherosclerosis and CVD risk (coronary artery disease, stroke, and peripheral vascular disease) (81).

Mitochondria and ATP/NA in ovary

The electron transport chain activity products are both mtROS and adenosine 5'-triphosphate (ATP) which ATP as a major intracellular energy (powerhouse) basis is an excitatory cotransmitter for the autonomic nervous system (ANS). ATP through oxidative phosphorylation is colocalized with NA in the vesicles of synaptic cleft at the postganglionic sympathetic nerves (27). The ratio of ATP to NA differs between different sympathetic nerve fibers. These nerves change through growth and in some pathological conditions, like hypertension. ATP as a cotransmitter and NA have synergistic actions in the postjunctional (28).

Intercellular messengers (para-crine-signaling) are very critical in ovarian physiology for folliculogenesis and steroidogenesis. The purinergic system (ATP) is one of the vital intra-ovarian modulator, because it can regulate proliferation, steroidogenesis and apoptosis processes in the response to gonadotropic hormones (GnRH) (29). Several P2 receptors with essential roles have been found in the ovary. Wang and et al., (2015) showed P2X7 receptor was exactly expressed on the porcine ovarian thecal and murine luteal cells and the activation of P2X7 decreased cell proliferation and encouraged apoptosis via calcium-dependent manner (30). Luteal phase deficiency (LPD) is a major cause for female infertility and nucleotides receptors (P2) can be released of sympathetic nerve ending and be influential on the corpus luteum function. Therefore, exploring of purinergic signaling and SNS (ATP/NA) in luteal cells can be having suggestions for treatment of the luteal phase inadequacy. In the luteal phase the corpus luteum (CL) is made by the luteinizing hormone (LH) function on the mature preovulatory follicle. CL is a transitory endocrine gland that is vital for mammalian's pregnancy. There is the continual dependency in the primate CL on LH/CG/cAMP which seems to trigger luteolysis that can provide by the endogenous LH pulses (31). Acquisition of LH receptor (LHR) by preovulatory granulosa cells results from estrogen-stimulated and FSH-stimulated transcription of the LHR gene,

the actions of which are mediated largely by intracellular cyclic adenosine monophosphate (cAMP).³²

In women with PCOS, infertility could result from the corpus luteum (CL) dysfunctional (32).

Recent developments of the inflammatory triggers in women with PCO show the innate immune responses. PCOS is a chronic low-grade inflammation disease (27) which was associated by metabolic abnormalities like IR that has a potent link with chronic inflammation which were higher in overweight PCO patients (28).

References

1. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. *Cochrane Database Syst Rev.* 2011; 162:CD007506.
2. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. *Reprod Biol Endocrinol.* 2011;9:39.
3. Melo AS, Vieira CS, Barbieri MA, Rosa-E-Silva AC, Silva AA, Cardoso VC, et al. High prevalence of polycystic ovary syndrome in women born small for gestational age. *Hum Reprod.* 2010; 25: 2124–31.
4. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. *Human Reproduction Update.* 2010; 16: 347-363.
5. Chereau A. *Mémoires pour Servir à l'Étude des Maladies des Ovaires.* Paris, France: Fortin, Masson; 1844.
6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) *Human Reproduction.* 2004; 19: 41-47.
7. Peipei Jin & Yongyong Xie. Treatment strategies for women with polycystic ovary syndrome. *Gynecol Endocrinol.* 2017; 31:1-6.
8. Alchami A, O'Donovan O, Davies M. PCOS: diagnosis and management of related infertility. *Obstetrics, Gynecology & Reproductive Medicine.* 2015; 25: 279-282.
9. Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: a review. *European Journal of Medicinal Chemistry.* 2015; 97: 55-74.
10. Cadenas E. Biochemistry of oxygen toxicity. *Ann Rev Biochem.* 1989; 58: 79-110.
11. Sharlip ID, Jarow JP, Belker AM, Lipshultz LI, Sigman M, Thomas AJ, et al. Best practice policies for male infertility. *Fertility and sterility.* 2002;77: 873.
12. Agarwal A, Gupta S, Sekhon L, Shah R. Redox considerations in female reproductive function and assisted reproduction: From molecular mechanisms to health implications. *Antioxid Redox Signal.* 2008; 10: 1375-403.
13. Riley PA. Free radicals in biology: oxidative stress and effects of ionizing radiation. *Int J Rad Biol.* 1994; 65: 27-33.
14. Cadenas E, Davies KJA. Mitochondrial free radical generation, oxidative stress, and aging. *Free Rad Biol Med.* 2000; 29: 222-30.

15. Koliaki C, Roden M. Alterations of mitochondrial function and insulin sensitivity in human obesity and diabetes mellitus. *Annu. Rev. Nutr.* 2016;36:337–367.
16. Martin S.D., McGee S.L. The role of mitochondria in the aetiology of insulin resistance and type 2 diabetes. *Biochim. Biophys. Acta Gen. Subj.* 2014; 1840: 1303–1312.
17. Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell death. *Apoptosis.* 2007; 12:913-22.
18. Zuo L, Prather ER, Stetskiv M, Garrison DE, Meade JR, Peace TI, Zhou T. Inflammaging and oxidative stress in human diseases: from molecular mechanisms to novel treatments. *Int J Mol Sci.* 2019; 20:4472.
19. Angajala A, Lim S, Phillips JB, Kim JH, Yates C, You Z, Tan M. Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism. *Front Immunol.* 2018; 9:1605.
20. Cronkite DA, Strutt TM. The Regulation of Inflammation by Innate and Adaptive Lymphocytes. *J Immunol Res.* 2018 Jun 11; 2018:1467538.
21. Siti HN, Kamisah Y, Kamsiah J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). *Vascular Pharmacology.* 2015; 71: 40–56.
22. Haas MJ, Jurado-Flores M, Hammoud R, Feng V, Gonzales K, Onstead-Haas LD, Mooradian A. Inhibition of Pro-Inflammatory Cytokine Secretion by Select Antioxidants in Human Coronary Artery Endothelial Cells. *Int J Vitam Nutr Res.* 2020; 90:103-112.
23. Tan BL, Norhaizan ME, Liew WP, Sulaiman Rahman H. Antioxidant and oxidative stress: A mutual interplay in age-related diseases. *Front Pharmacol.* 2018; 9:1162.
24. Huang HY, Helzlsouer KJ, Appel LJ. The effects of vitamin C and vitamin E on oxidative DNA damage: results from a randomized controlled trial. *Cancer Epidemiol Biomarkers Prev.* 2000; 9: 647-52.
25. Pizzino G, Irrera N, Cucinotta M, Cucinotta M, Pallioet G. Oxidative Stress: Harms and Benefits for Human Health. *Oxid Med Cell Longev.* 2017; 2017:8416763.
26. Ilie IR. Advances in PCOS pathogenesis and progression-mitochondrial mutations and dysfunction. *Adv Clin Chem.* 2018; 86: 127-155.
27. Siti HN, Kamisah Y, Kamsiah J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). *Vascular Pharmacology.* 2015; 71: 40–56.
28. Tiwari BK, Pandey KB, Abidi AB, Rizvi SA. Markers of Oxidative Stress during Diabetes Mellitus. *Journal of Biomarkers.* 2013; 2013: Article ID 378790, 8 pages.
29. Salim s. Oxidative Stress and Psychological Disorders. *Curr Neuropharmacol.* 2014; 12: 140-147.
30. Sosaa V, Molinéa T, Somozaa R, Paciuccib R, LLeonarta ME. Oxidative stress and cancer: An overview. *Ageing Research Reviews.* 2014; 12: 376-390.
31. Papalou O, Victor VM, Diamanti-Kandarakis E. Oxidative Stress in Polycystic Ovary Syndrome. *Curr Pharm Des.* 2016; 22:2709-22.
32. Tönnies E, Trushina E. Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease. *J Alzheimers Dis.* 2017; 57:1105–1121.
33. Ohl K, Tenbrock K, Kipp M. Oxidative stress in multiple sclerosis: Central and peripheral mode of action. *Exp Neurol.* 2016; 277:58-67.
34. Abuelo A, Hernández J, Benedito JL, Castillo C. Oxidative stress index (OSi) as a new tool to assess redox status in dairy cattle during the transition period. *Animal.* 2013; 7: 1374-8
35. Sánchez-Rodríguez MA, Mendoza-Núñez VM. Oxidative Stress Indexes for Diagnosis of Health or Disease in Humans. *Oxidative Medicine and Cellular Longevity.* 2019; Article ID 4128152: 32 pages.
36. Mohamadin AM, Habib FA, Elahi TF. Serum paraoxonase 1 activity and oxidant/antioxidant status in Saudi women with polycystic ovary syndrome. *Pathophysiology.* 2010; 17: 189–196.

37. Sak S , Uyanikoglu H , Incebiyik A , Incebiyik H , Hilali NG , Sabuncu T , Sak E. Associations of serum fetuin-A and oxidative stress parameters with polycystic ovary syndrome. *Clin Exp Reprod Med.* 2018; 45:116-121.
38. Deepika M. L. N., Nalini S., Maruthi G., et al. Analysis of oxidative stress status through MN test and serum MDA levels in PCOS women. *Pakistan Journal of Biological Sciences.* 2014; 17: 574–577.
39. Seleem A. K., El Refaeey A. A., Shaalan D., Sherbiny Y., Badawy A. Superoxide dismutase in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection. *Journal of Assisted Reproduction and Genetics.* 2014; 31: 499–504.
40. Baskol G, Aygen E, Erdem F, Caniklioglu A, Narin F, Sahin Y, Kaya T. Assessment of paraoxonase 1, xanthine oxidase and glutathione peroxidase activities, nitric oxide and thiol levels in women with polycystic ovary syndrome. *Acta Obstetricia Gynecologica Scandinavica.* 2012; 91: 326–330.
41. Savic-Radojevic A, Bozic Antic I, Coric V, Bjekic-Macut J, Radic T, Zarkovic M, Djukic T, Pljesa-Ercegovac M, Panidis D, Katsikis I, Simic T, Macut D. Effect of hyperglycemia and hyperinsulinemia on glutathione peroxidase activity in non-obese women with polycystic ovary syndrome. *Hormone.* 2015; 14: 101-108.
42. Sova H., Morin-Papunen L., Puistola U., Karihtala P. Distinctively low levels of serum 8-hydroxydeoxyguanosine in women with polycystic ovary syndrome. *Fertility and Sterility.* 2010; 94: 2670–2673.
43. Liu J, Zhang D. The role of oxidative stress in the pathogenesis of polycystic ovary syndrome. *Sichuan Da Xue Xue Bao Yi Xue Ban.* 2012; 43: 187–190.
44. Nasiri N, Moini A, Eftekhari-Yazdi P, Salman-Yazdi R, Zolfaghari Z, Arabipoor A. Abdominal obesity can induce both systemic and follicular fluid oxidative stress independent from polycystic ovary syndrome. *European Journal of Obstetrics Gynecology and Reproductive Biology.* 2015; 184: 112-116.
45. Savic-Radojevic A, Bozic Antic I, Coric V, Bjekic-Macut J, Radic T, Zarkovic M, Djukic T, Pljesa-Ercegovac M, Panidis D, Katsikis I, Simic T, Macut D. Effect of hyperglycemia and hyperinsulinemia on glutathione peroxidase activity in non-obese women with polycystic ovary syndrome. *Hormone.* 2015; 14: 101-108.
46. González F, Sreekumaran Nair K, Daniels JK, Basal E, Schimke JM. Hyperandrogenism sensitizes mononuclear cells to promote glucose-induced inflammation in lean reproductive-age women. *American Journal of Physiology—Endocrinology and Metabolism.* 2012; 302: E297-E306.
47. Federico A, Morgillo F, Tuccillo C, Ciardiello F., Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. *International Journal of Cancer.* 2007; 121: 2381-2386.
48. Das S, Chattopadhyay R, Ghosh S, Ghosh S, Goswami SK, Chakravarty BN, Chaudhury K. Reactive oxygen species level in follicular fluid--embryo quality marker in IVF? *Hum Reprod.* 2006; 21:2403-7.
49. Zuo T, Zhu M, Xu W. Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers. *Oxid Med Cell Longev.* 2016; 2016: 8589318.
50. Sak S, Uyanikoglu H, Incebiyik A, Incebiyik H, Hilali NG, Sabuncu T, Sak E. Associations of serum fetuin-A and oxidative stress parameters with polycystic ovary syndrome. *Clin Exp Reprod Med.* 2018 Sep; 45(3): 116–121.
51. Zhang J, Bao Y, Zhou X, Zheng L. Polycystic ovary syndrome and mitochondrial dysfunction. *Reprod Biol Endocrinol.* 2019; 17: 67-82.
52. Lansdown A, Rees DA. The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target? *Clin Endocrinol (Oxf).* 2012; 77: 791-801.

53. Cruz G, Fernandois D, Paredes AH. Ovarian function and reproductive senescence in the rat: role of ovarian sympathetic innervation. *Reproduction*. 2017; 153: R59–R68.
54. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. *Endocr Rev*. 2016; 37: 467–520.
55. Disen GA, Garcia-Ruda C, Paredes A, Mayer C, Mayerhofer A, Ojeda SR. Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans. *Endocrinology*. 2009; 150: 2906-2914.
56. Zangeneh FZ, Bagheri M, Naghizadeh MM. Hyponeurotrophinemia in Serum of Women with polycystic ovary syndrome as a low grade chronic inflammation. *Open Journal of Obstetrics and Gynecology*. 2015; 5: 459-469.
57. Kishi T. Regulation of the sympathetic nervous system by nitric oxide and oxidative stress in the rostral ventrolateral medulla: 2012 Academic Conference Award from the Japanese Society of Hypertension. *Hypertens Res*. 2013; 36: 845-51.
58. Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, Joham AE, Cooray SD, Misso ML, Norman RJ, Harrison CL, Ranasinha S, Teede HJ, Moran LJ. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. *Obes Rev*. 2019; 20: 339-352.
59. Ciccarelli C, Santulli G, Pascale V, Trimarco B, Iaccarino G. Adrenergic receptors and metabolism: role in development of cardiovascular disease. *Front Physiol*. 2013; 4: 265-270.
60. Lara HE, Dorfman M, Venegas M, Luza SM, Luna SL, Mayerhofe A, et al. Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: Studies on norepinephrine release. *Microsc Res Tech*. 2002; 59: 495-502.
61. Tellechea ML, Muzzio DO, Iglesias Molli AE, Belli SH, Graffigna MN, Levalle OA, Frechtel GD, Cerrone GE. Association between β 2-adrenoceptor (ADRB2) haplotypes and insulin resistance in PCOS. *Clin Endocrinol (Oxf)*. 2013; 78: 600-6.
62. Zangeneh FZ, Abdollahi A, Aminee F, Naghizadeh MM. Locus coeruleus lesions and PCOS: role of the central and peripheral sympathetic nervous system in the ovarian function of rat. *Iran J Reprod Med*. 2012; 10: 113–120.
63. Patel K, Coffler MS, Dahan MH, Malcom PJ, Deutsch R, Chang RJ. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome. *Clinical Endocrinology*. 2004; 60: 67–74.
64. Lobo RA, Granger LR, Paul WL, Goebelsmann U, Mishell DR Jr. Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome. *Am J Obstet Gynecol*. 1983; 145: 496-503.
65. Barria A, Leyton V, Ojeda SR, Lara HE. Ovarian steroidal response to gonadotropins and beta-adrenergic stimulation is enhanced in polycystic ovary syndrome: role of sympathetic innervation. *Endocrinology* 1993; 133: 2696-2703.
66. Desai V, Prasad NR, Manohar SM, Sachan A, Narasimha SR, Bitla AR. Oxidative Stress in Non-Obese Women with Polycystic Ovarian Syndrome. *J Clin Diagn Res*. 2014; 8: CC01-CC03.
67. Bañuls C, Rovira-Llopis S, Martínez de Marañón A, Veses S, Jover A, Gomez M, Rocha M, Hernandez-Mijares A, Victor VM. Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte-endothelium interactions in PCOS. *Metabolism*. 2017; 71: 153-162.
68. Victor VM, Rovira-Llopis S, Bañuls C, Diaz-Morales N, Martínez de Marañón A, Rios-Navarro C, Alvarez A, Gomez M1, Rocha M1, Hernández-Mijares A. Insulin Resistance in

- PCOS Patients Enhances Oxidative Stress and Leukocyte Adhesion: Role of Myeloperoxidase. *PLoS One*. 2016;11:e0151960.
69. Lee SH, Zabolotny JM, Huang H, Lee H, Kim Y. Insulin in the nervous system and the mind: Functions in metabolism, memory and mood. *Mol Metab*. 2016; 5: 589–601.
 70. Air EL, Strowsk,MZ, Benoit SC, Conarello SL, Salituro GM,Guan XM. Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. *Nat Med* 2002b; 8:179-183.
 71. Timper K, Brüning J. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. *Dis Model Mech*. 2017; 10: 679–689.
 72. Falkowska A, Gutowska I, Goschorska M, Nowacki P, Chlubek D,Baranowska-Bosiacka I. Energy Metabolism of the Brain, Including the Cooperation between Astrocytes and Neurons, Especially in the Context of Glycogen Metabolism. *Int J Mol Sci*. 2015; 16: 25959-25981.
 73. Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, Calvo M, Bermúdez V. Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. *International Journal of Reproductive Medicine*. 2014; 2014; Article ID 719050, 17 pages.
 74. Bairey Merz CN, Elboudwarej O, Mehta P. The autonomic nervous system and cardiovascular health and disease: a complex balancing act. *JACC Heart Fail*. 2015; 3: 383-385.
 75. Chen C, Smothers J, Lange A, Nestler JE, Strauss Iii JF, Wickham Iii EP. Sex hormone-binding globulin genetic variation: associations with type 2 diabetes mellitus and polycystic ovary syndrome. *Minerva Endocrinol*. 2010; 35: 271-80.
 76. Nitsche K, Ehrmann DA. Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. *Best Pract Res Clin Endocrinol Metab* 2010; 24: 717-30.
 77. Zangeneh FZ. Polycystic ovary syndrome and sympathoexcitation: management of stress and lifestyle. *Journal of Biology and Today's world*. 2017; 6:146-154.
 78. Mancía G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van Zwieten PA. The sympathetic nervous system and the metabolic syndrome. *J Hypertens*. 2007; 25: 909-20.
 79. Mahalingaiah S, Diamanti-Kandarakis E. Targets to treat metabolic syndrome in polycystic ovary syndrome. *Expert Opin Ther Targets*. 2015; 19: 1561–1574.
 80. Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, Joham AE, Cooray SD, Misso ML, Norman RJ, Harrison CL, Ranasinha S, Teede HJ, Moran LJ. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. *Obes Rev*. 2019; 20: 339-352.
 81. Zhu S, Zhang B, Jiang X, Li Z, Zhao S, Cui L, Chen ZJ .Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. *Fertil Steril*. 2019; 111: 168-177.